Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus Fluorouracil/Cisplatin | Zendy

Leonard L. Gunderson | Zendy; Kathryn Winter | Zendy; Jaffer A. Ajani | Zendy; John E. Pedersen | Zendy; Jennifer Moughan | Zendy; Al B. Benson | Zendy; Charles R. Thomas | Zendy; Robert J. Mayer | Zendy; Michael G. Haddock | Zendy; Tyvin A. Rich | Zendy; Christopher G. Willett | Zendy

Open Access

Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus Fluorouracil/Cisplatin

Author(s) -

Leonard L. Gunderson,

Kathryn Winter,

Jaffer A. Ajani,

John E. Pedersen,

Jennifer Moughan,

Al B. Benson,

Charles R. Thomas,

Robert J. Mayer,

Michael G. Haddock,

Tyvin A. Rich,

Christopher G. Willett

Publication year - 2012

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2012.43.8085

Subject(s) - medicine , fluorouracil , radiation therapy , proportional hazards model , log rank test , oncology , hazard ratio , cisplatin , carcinoma , survival analysis , surgery , gastroenterology , chemotherapy , confidence interval

On initial publication of GI Intergroup Radiation Therapy Oncology Group (RTOG) 98-11 [A Phase III Randomized Study of 5-Fluorouracil (5-FU), Mitomycin, and Radiotherapy Versus 5-Fluorouracil, Cisplatin and Radiotherapy in Carcinoma of the Anal Canal], concurrent chemoradiation (CCR) with fluorouracil (FU) plus mitomycin (MMC) decreased colostomy failure (CF) when compared with induction plus concurrent FU plus cisplatin (CDDP), but did not significantly impact disease-free survival (DFS) or overall survival (OS) for anal canal carcinoma. The intent of the updated analysis was to determine the long-term impact of treatment on survival (DFS, OS, colostomy-free survival [CFS]), CF, and relapse (locoregional failure [LRF], distant metastasis) in this patient group.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research